Eli Lilly的新减重药丸很有前途, 导致肥胖成人平均损失27磅。 Eli Lilly's new weight-loss pill shows promise, leading to average 27-pound loss in obese adults.

艾利利利公司报告了其新型减肥药"奥福格利"的第三期试验的积极结果, 在72周的时间里, 肥胖的成人没有糖尿病的体重平均减轻了27.3磅 (12.4%). Eli Lilly has reported positive results from a Phase 3 trial for its new weight-loss pill, orforglipron, which led to an average weight loss of 27.3 pounds (12.4%) over 72 weeks in obese adults without diabetes. 该药物还改善了心血管风险因素,尽管引起了一些肠胃问题,但总的来说,该药物得到了良好的免疫力。 The drug also improved cardiovascular risk factors and was generally well-tolerated, though it caused some gastrointestinal issues. 莉莉计划到年底将避孕药提交监管批准,目的是为目前可注射的肥胖症治疗提供方便的口服替代方法。 Lilly plans to submit the pill for regulatory approval by year-end, aiming to provide a convenient oral alternative to current injectable treatments for obesity.